Insulet (NSDQ:PODD) said today that it inked a deal with Glooko to connect data from Insulet’s Omnipod insulin delivery devices in Europe with the Glooko+diasend diabetes data management system.
Glooko touted that its data management tech is used at roughly 7,000 provider sites across 23 countries. The Glooko+diasend system allows users to sync and review data from an array of diabetes devices, giving them insights into their insulin regimen.
Get the full story at our sister site, Drug Delivery Business News.
The post Insulet extends deal with Glooko in Europe appeared first on MassDevice.